Sana Biotechnology, Inc. (SANA)

Sana Biotechnology’s preliminary results for the second fiscal quarter of 2026 trailed consensus on EPS, with the company reporting -$0.22 versus an estimate of -$0.15 (difference -$0.07), alongside a GAAP net loss that narrowed year over year; the quarter was reported August 11, 2026. Net income improved ~32% to a loss of about $63.6 million, up from a loss of about $93.8 million a year ago, while operating income came in at a loss of roughly $65.4 million. The reported EPS loss of -$0.22 also improved ~44% from -$0.39 a year earlier, despite trailing the Street’s estimate for the quarter. Cash flow from operations was negative, at roughly -$32.8 million. For the next period, consensus calls for EPS of -$0.18.